Abstract: The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.

Abstract: Compounds useful as prodrugs of potassium channel inhibitor compounds, in particular as prodrugs of Kv1.5 channel inhibitors.

Abstract: A method is provided for treating diabetes and related diseases, especially Type II diabetes, employing an aP2 inhibitor or a combination of an aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.

Abstract: The present invention provides pyrazole derived compounds of formula (I) useful for treating p38 kinase-associated conditions, where G, X, R1, R2, R3, R4, R5, R6 and m are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p38 kinase-associated conditions, and methods of inhibiting the activity of p38 kinase in a mammal.

Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R6, R7, m and n are described herein.

Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R3a, R4, A, B, n, Y and Z are described herein.

Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R3a, R4, A, B, b, n, W, X, Y and Z are described herein.

Abstract: A method is provided for treating atherosclerosis and related diseases, employing an aP2 inhibitor or a combination of an aP2 inhibitor and another antiatherosclerotic agent, for example, an HMG CoA reductase inhibitor such as pravastatin.

Abstract: The present invention provides thiazolyl-based compounds of formula (I), useful for treating p38 kinase-associated conditions, wherein ring A is phenyl or pyridyl, and X, Y, B, R2, R3, Z1 m and n are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p38 kinase-associated conditions, and methods of inhibiting the activity of p38 kinase in a mammal.

Abstract: The invention provides a drug delivery system for delivering a drug to either the small intestine (enteric) or the colon comprising a HPMC capsule containing the drug and wherein the HPMC capsule is provided with a suitable coating such that the drug is released from the capsule either in the small intestine or the colon.

Abstract: The invention concerns polyvinyl alcohol (PVA) compositions for the use in pharmaceutical, veterinary, food, cosmetic or other products like films for wrapping food, aspics or jellies, preferably for predosed formulations like soft or hard capsules. Compared with hard gelatine capsules (HGC) capsule films consisting of PVA have extremely low water vapour permeability and much lower water content.

Abstract: The invention concerns, film-forming compositions containing pectin, at least one additional film-forming polymer and a setting system for use in pharmaceutical, veterinary, food, cosmetic or other products like films for wrapping food, aspics or jellies, preferably for predosed formulations like soft or hard capsules, as well as aqueous solutions of the composition for the manufacturing of said products.

Abstract: The invention concerns Gelatin compositions for the use in pharmaceutical, veterinary, food, cosmetic or other products like films for wrapping food, aspics or jellies, preferably for predosed formulations like soft or hard gelatin capsules wherein the gelatin used is of non-bovine and non-pig origin and preferably derived from fish, poultry or plant sources. Especially preferred are film compositions for hard gelatine capsules prepared from fish gelatin.

Abstract: A topical composition suitable for application to skin comprising an amount of antioxidant action vitamin and vitamin precursor sufficient to bring about an effect selected from the group consisting of a level of vitamin on the skin significantly above the amount of vitamin on normal vitamin untreated skin for a period of treating four hours after application of the said vitamin containing composition, a reduction of lipid peroxide levels brought about by an insult to the skin wherein the skin is treated with the said vitamin containing composition prior to said insult, a level of skin vitamin which is significantly above the level of vitamin on the skin brought about by oral ingestion of the vitamin, or a combination of any of a, b, or c.

Abstract: This invention comprises low residue cosmetic compositions (especially underarm products) which are made by combining an active ingredient; a silicone gel material itself comprising an elastomer composition; and at least one selected surfactant having an HLB value in the range of 8-16. The compositions of this invention exhibit reduced or eliminated film formation when applied to the skin and increased availABILity of the active ingredient.

Abstract: This invention relates to an anhydrous cosmetic composition comprising: (a) 15-33% of an external phase (also called the oil phase) which is made with at least one selected naphthalate organic ester; a volatile silicone based emulsifier; and a volatile silicone; and (b) 85-67% of an internal phase which is made with an active ingredient, such as an antiperspirant active, in a glycol solvent. For the external phase all or a major portion of what would have been a non-volatile silicone component has been replaced by the naphthalate ester. While a dimethicone copolyol is still included, the use of this particular naphthalate ester obviates the need for the use of any other non-ionic emulsifiers.

Abstract: A pearlized cleansing composition for personal care comprising: (a) 4.00-30.00 weight % of an anionic material selected from the group consisting of water soluble lipophilic sulfates and sulfonates of 8 to 22 carbon atoms; (b) 0.25-4.0 weight % behenyl alcohol; and (c) water.

Abstract: A high efficacy antiperspirant/deodorant stearyl alcohol free stick product may be made by combining (a) 30-70% volatile cyclomethicone; (b) 10-25% of an antiperspirant active; (c) 1-15% of an emollient; (d) 1-14% of polyethylene comprising one or more members selected from the group consisting of homopolymers and copolymers of polyethylene wherein the polyethylene (i) is at least 90% linear; (ii) has a molecular weight in the range of 300-3000 (especially 300-1000 and more especially 300-500); (iii) has a melting point in the range of 50-129 degrees C.; and (iv) has a polymer backbone of CH3CH2—(CH2—CH2)n—H, where n is an average number and is selected to be in the range of 10-106; (e) 0.3-7% of a wax as a co-gellant with the polyethylene wherein the wax has a melting point in the range of 40-97 degrees C.; and (f) 1-40% of an elastomer in cyclomethicone composition; provided that the ratio of wax:polyethylene is in the range of 1:1-1:10.

Abstract: The present invention utilizes a polyethylene glycol diisostearate having an average degree of ethoxylation of from 40-100 as a component of a soap-based gel composition suitable for use in formulating stable cosmetic compositions, especially low irritancy deodorants.

Abstract: A two-phase roll-on antiperspirant and/or deodorant is described which comprises: (a) a clear, translucent or opaque non-polar phase having a viscosity in the range of 20 cps-9,000 made by combining: a cross-linked or partially cross-linked non-emulsifying siloxane elastomer; 0.1-70 weight % of one or more low viscosity, lipophilic emollients; (b) a clear, translucent or opaque polar phase have a viscosity in the range of 20-9,000 cps made by combining: one or more members selected from the group consisting of water, glycols and polyhydric alcohols; and an antiperspirant active salt which is soluble or suspendible in the polar phase; wherein the polar phase comprises (i) a sufficient amount of water, glycols or polyhydric alcohols to dissolve or suspend the antiperspirant active, and (ii) optionally may comprise up to 30 weight % water; up to 16.00 weight % of ethyl alcohol; up to 16 weight % isopropyl alcohol; or mixtures of the foregoing; (iii) 0.1-2.